DNA topoisomerase I inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “DNA topoisomerase I inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase I inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
DNA topoisomerase I inhibitors: Overview
DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.
Report Highlights
This segment of the DNA topoisomerase I inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA topoisomerase I inhibitors Emerging Drugs
Further product details are provided in the report……..
DNA topoisomerase I inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA topoisomerase I inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
DNA topoisomerase I inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA topoisomerase I inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase I inhibitors drugs.
DNA topoisomerase I inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “DNA topoisomerase I inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase I inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
DNA topoisomerase I inhibitors: Overview
DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase I inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase I inhibitors.
This segment of the DNA topoisomerase I inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA topoisomerase I inhibitors Emerging Drugs
- Sacituzumab govitecan: Immunomedics
- Trastuzumab Deruxtecan: Daiichi Sankyo
Further product details are provided in the report……..
DNA topoisomerase I inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA topoisomerase I inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on DNA topoisomerase I inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
DNA topoisomerase I inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA topoisomerase I inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase I inhibitors drugs.
DNA topoisomerase I inhibitors Report Insights
- DNA topoisomerase I inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing DNA topoisomerase I inhibitors drugs?
- How many DNA topoisomerase I inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of DNA topoisomerase I inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase I inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for DNA topoisomerase I inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Immunomedics
- Daiichi Sankyo
- Ipsen
- Luye Pharma Group
- Hanmi Pharmaceutical
- Biocompatibles International
- Valent Technologies
- Elucida Oncology
- Cybrexa Therapeutics
- Linus Oncology
- Lee's Pharmaceutical
- SN BioScience
- Cebiotex
- Sacituzumab govitecan
- Trastuzumab deruxtecan
- Irinotecan sucrosofate
- DS-1062
- LY 01610
- Irinotecan/encequidar
- CM-BC2
- VAL-413
- DS 6000
- CEB-01
- SN 38
- ELU 001
- Gimatecan
- LMP 744
- CBX-12
Introduction
Executive Summary
DNA topoisomerase I inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA topoisomerase I inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sacituzumab govitecan: Immunomedics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Irinotecan hydrochloride liposomal: Luye Pharma Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Irinotecan: Valent Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA topoisomerase I inhibitors Key Companies
DNA topoisomerase I inhibitors Key Products
DNA topoisomerase I inhibitors- Unmet Needs
DNA topoisomerase I inhibitors- Market Drivers and Barriers
DNA topoisomerase I inhibitors- Future Perspectives and Conclusion
DNA topoisomerase I inhibitors Analyst Views
DNA topoisomerase I inhibitors Key Companies
Appendix
Executive Summary
DNA topoisomerase I inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA topoisomerase I inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sacituzumab govitecan: Immunomedics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Irinotecan hydrochloride liposomal: Luye Pharma Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Irinotecan: Valent Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA topoisomerase I inhibitors Key Companies
DNA topoisomerase I inhibitors Key Products
DNA topoisomerase I inhibitors- Unmet Needs
DNA topoisomerase I inhibitors- Market Drivers and Barriers
DNA topoisomerase I inhibitors- Future Perspectives and Conclusion
DNA topoisomerase I inhibitors Analyst Views
DNA topoisomerase I inhibitors Key Companies
Appendix